4:07 PM
 | 
Dec 02, 2016
 |  BC Extra  |  Company News

Celgene acquiring Acetylon after spinout of newco

Acetylon Pharmaceuticals Inc. (Boston, Mass.) said Celgene Corp. (NASDAQ:CELG) will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.).

Celgene will gain rights to Acetylon's lead candidates, oral HDAC6 inhibitors ricolinostat (

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >